Goldman Sachs Maintains Neutral on Celldex Therapeutics, Raises Price Target to $34
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst Richard Law maintains Celldex Therapeutics (NASDAQ:CLDX) with a Neutral and raises the price target from $30 to $34.
Goldman Sachs analyst Richard Law maintains Celldex Therapeutics (NASDAQ:CLDX) with a Neutral and raises the price target from $30 to $34.